Fortress Biotech Inc.9.375 % Cum Conv Stock News

Fortress Biotech, Inc. (NASDAQ:FBIO ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Matt Blazei - CORE IR Claude Maraoui - Co-Founder President and Chief Executive

Journey Medical Corporation (NASDAQ:FBIO ) Q2 2022 Results Conference Call August 9, 2022 4:30 PM ET Company Participants Claude Maraoui - Co-Founder President and Chief Executive Officer Ernest De Pa

The following slide deck was published by Fortress Biotech, Inc. in conjunction with this event..

The following slide deck was published by Fortress Biotech, Inc. in conjunction with this event..

NEW YORK, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or mon

Product revenue for the first six months of 2020 increased 50% year-over-year to $21.4 million Agreement executed with Columbia University to develop novel oligonucleotide platform for the treatment

LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively onlin

LOS ANGELES, CA / ACCESSWIRE / August 3, 2020 / The SNN Network Virtual Conference will take place on August 3rd \\- 6th, 2020, where 49 SmallCap, MicroCap and NanoCap public companies will be present

Rolling submission of New Drug Application to the FDA for CUTX-101 on track to begin in the fourth quarter of 2020NEW YORK, July 31, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“

Cyprium Therapeutics, a Fortress partner company, is developing CUTX-101 for Menkes disease A rolling submission of a New Drug Application to the FDA is expected to begin in the fourth quarter of 202

NEW YORK, July 21, 2020 -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today.

Fortress Biotech, Inc.'s (NASDAQ:FBIO): Fortress Biotech, Inc. develops and commercializes pharmaceutical and...

In this article we will check out the progression of hedge fund sentiment towards Fortress Biotech Inc (NASDAQ:FBIO) and determine whether it is a good investment right now. We at Insider Monkey like

Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company, today announced that it has priced an underwritten publi

Fortress appointed ThinkEquity, a division of Fordham Financial Management, Inc.  to purchase the stock on behalf of the Company in conformity with the provisions of Rule 10b-18 under the Securities